
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
“China is the next logical step for us,” said Bruce Schatzman, Founder and Chief Executive Officer of StudyManager. “Because the cost of paper trials in China is still very competitive, we believe our EDC solution is a great choice when Chinese CROs and sponsors don’t see the price/performance value offered by larger EDC providers.”
To accomadate Asian expansion, StudyManager opened a data center in Shanghai, from which Chinese companies can run its EDC/CTMS system in what it calls "a secure and compliant manner."






